title: Retreatment with interferon and ribavirin vs interferon alone according to viraemia in interferon responder-relapser hepatitis C patients: a prospective multicentre randomized controlled study.
abstract: Low pretreatment viral load has consistently been shown to be an independent predictor of sustained response (SR) in patients with chronic hepatitis C infection. We assessed the efficacy of interferon (IFN) plus ribavirin vs IFN alone in low viraemic patients (<2 millions copies/mL) who had relapsed to a previous course of IFN and the efficacy of 24 vs 48 week combination therapy in high viraemic patients. Two hundred and ninety-seven patients were randomly assigned to one of the four regimens after stratification on pretreatment viral load. All patients received IFN-alpha2b (6 million units thrice weekly for 24 weeks and 3 million units thrice weekly for 24 weeks). Patients with low viraemia received either IFN-alpha2b alone for 48 weeks (R1: 42 patients) or IFN-alpha2b plus ribavirin (600 mg/day) for 24 weeks and IFN-alpha2b alone for the next 24 weeks (R2: 48 patients). Patients with high viral load received either IFN-alpha2b plus ribavirin for 24 weeks and then IFN-alpha2b alone for the next 24 weeks (R3: 104 patients) or IFN-alpha2b plus ribavirin for 48 weeks (R4: 103 patients). In low viraemic patients the rate of SR was 37.7% in group R1 and 59.6% in group R2 (P < 0.05). In high viraemic patients, the rate of SR was 44.7% in group R3 and 51.4% in group R4 (P: NS). Thirty-one patients discontinued treatment (10.4%) without difference regarding treatment regimen. In the regimen using ribavirin we found no difference in terms of SR between patients receiving a dose of ribavirin below 10.6 mg/kg/day (55%) or over 10.6 mg/kg/day (58%). Histological improvement occurred in 70.2% of patients regardless of the regimen. Logistic regression showed that genotype 2 and 3, Knodell score <6 and alanine aminotransferase pretreatment level >3 x upper limit of normal were significantly and independently correlated with SR. In low viraemic patients who relapsed to a previous IFN treatment, combination therapy using high-dose IFN and low-dose ribavirin is better than high-dose IFN alone. In high viraemic patients there was no benefit in increasing the duration of combination therapy from 24 to 48 weeks. In this study, it was found that low dose of ribavirin can be used safely and there is no effect of ribavirin dose on SR.
authors.affiliation: Department of Hepato-gastroenterology, Hospital La Conception, 13008 Marseille, France.
authors.forename: I
authors.initials: I
authors.lastname: Portal
authors.forename: M
authors.initials: M
authors.lastname: Bourlière
authors.forename: P
authors.initials: P
authors.lastname: Halfon
authors.forename: V
authors.initials: V
authors.lastname: De Lédinghen
authors.forename: P
authors.initials: P
authors.lastname: Couzigou
authors.forename: P H
authors.initials: PH
authors.lastname: Bernard
authors.forename: F
authors.initials: F
authors.lastname: Blanc
authors.forename: F
authors.initials: F
authors.lastname: Caroli-Bosc
authors.forename: J P
authors.initials: JP
authors.lastname: Arpurt
authors.forename: D
authors.initials: D
authors.lastname: Vetter
authors.forename: C
authors.initials: C
authors.lastname: Mathieu-Chandelier
authors.forename: O
authors.initials: O
authors.lastname: Chazouillères
authors.forename: G
authors.initials: G
authors.lastname: Thiefin
authors.forename: S
authors.initials: S
authors.lastname: Pol
authors.forename: P
authors.initials: P
authors.lastname: Sogni
authors.forename: A
authors.initials: A
authors.lastname: Abergel
authors.forename: F
authors.initials: F
authors.lastname: Bailly
authors.forename: M
authors.initials: M
authors.lastname: Picon
authors.forename: J M
authors.initials: JM
authors.lastname: Debonne
authors.forename: C
authors.initials: C
authors.lastname: Zamora
authors.forename: I
authors.initials: I
authors.lastname: Alleman
authors.forename: X
authors.initials: X
authors.lastname: Moreau
authors.forename: F
authors.initials: F
authors.lastname: Doll
authors.forename: C
authors.initials: C
authors.lastname: Eugène
authors.forename: S
authors.initials: S
authors.lastname: Ducloux
authors.forename: D
authors.initials: D
authors.lastname: Larrey
authors.forename: D
authors.initials: D
authors.lastname: Ouzan
authors.forename: J C
authors.initials: JC
authors.lastname: Grimaud
authors.forename: J
authors.initials: J
authors.lastname: Gouvernet
authors.forename: G
authors.initials: G
authors.lastname: Botti
authors.forename: V
authors.initials: V
authors.lastname: Gérolami
authors.forename: H
authors.initials: H
authors.lastname: Khiri
authors.forename: A
authors.initials: A
authors.lastname: Gérolami
authors.forename: A P
authors.initials: AP
authors.lastname: Gauthier
authors.forename: D
authors.initials: D
authors.lastname: Botta-Fridlund
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D016174:Hepacivirus / Q000187:drug effects / Q000502:physiology; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012367:RNA, Viral / Q000097:blood; D011994:Recombinant Proteins; D012008:Recurrence; D019233:Retreatment; D012254:Ribavirin / Q000627:therapeutic use*; D016896:Treatment Outcome; D019562:Viral Load; D014766:Viremia / Q000188:drug therapy* / Q000821:virology
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D012367:RNA, Viral; D011994:Recombinant Proteins; D012254:Ribavirin